tiprankstipranks
Advertisement
Advertisement

EPRX Stock Latest News

Eupraxia Pharmaceuticals management to meet with Oppenheimer
The FlyEupraxia Pharmaceuticals management to meet with Oppenheimer
4d ago
EPRX
Eupraxia Therapeutics: Upcoming RESOLVE Trial Readouts and Symptom-Focused Data Strategy Underpin Buy Rating on EP-104GI
PremiumRatings
Eupraxia Therapeutics: Upcoming RESOLVE Trial Readouts and Symptom-Focused Data Strategy Underpin Buy Rating on EP-104GI
11d ago
EPRX
Eupraxia Maintained at Buy as Analyst Reaffirms $16 Price Target on Differentiated EoE Opportunity
PremiumRatings
Eupraxia Maintained at Buy as Analyst Reaffirms $16 Price Target on Differentiated EoE Opportunity
11d ago
EPRX
Eupraxia Pharmaceuticals reports Q2 net income ($14.5M) vs ($8.7M) last year
PremiumThe Fly
Eupraxia Pharmaceuticals reports Q2 net income ($14.5M) vs ($8.7M) last year
21d ago
EPRX
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis
PremiumThe Fly
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis
22d ago
EPRX
Eupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI
PremiumCompany AnnouncementsEupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI
25d ago
6K
EPRX
Eupraxia Therapeutics: Buy Rating Reaffirmed on Advancing EoE Program and RESOLVE Phase 2b Readout, Price Target Maintained at $16
Premium
Ratings
Eupraxia Therapeutics: Buy Rating Reaffirmed on Advancing EoE Program and RESOLVE Phase 2b Readout, Price Target Maintained at $16
26d ago
EPRX
Buy Rating Reiterated on Eupraxia Ahead of Key EP-104GI Trial Data; $11 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on Eupraxia Ahead of Key EP-104GI Trial Data; $11 Price Target Maintained
26d ago
EPRX
Analyst Maintains Buy on Eupraxia as Lead Asset EP-104GI Shows Strong Efficacy, Safety and Expanding Esophageal Opportunities
PremiumRatings
Analyst Maintains Buy on Eupraxia as Lead Asset EP-104GI Shows Strong Efficacy, Safety and Expanding Esophageal Opportunities
27d ago
EPRX
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects
PremiumCompany Announcements
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects
27d ago
EPRX
Eupraxia Pharmaceuticals files $300M mixed securities shelf
PremiumThe Fly
Eupraxia Pharmaceuticals files $300M mixed securities shelf
1M ago
EPRX
EPRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
EPRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
EPRX
David Martin Reiterates Buy on Eupraxia Pharmaceuticals, Citing Strong KOL Support for EP-104GI’s Commercialization Potential
PremiumRatingsDavid Martin Reiterates Buy on Eupraxia Pharmaceuticals, Citing Strong KOL Support for EP-104GI’s Commercialization Potential
1M ago
EPRX
Sam Slutsky Reiterates Buy Rating on EP-104GI Developer, Maintains $16 Price Target
Premium
Ratings
Sam Slutsky Reiterates Buy Rating on EP-104GI Developer, Maintains $16 Price Target
1M ago
EPRX
Analyst Reiterates Buy on EPRX, Keeps EP-104GI Upside Reflected in Unchanged $11 Price Target
Premium
Ratings
Analyst Reiterates Buy on EPRX, Keeps EP-104GI Upside Reflected in Unchanged $11 Price Target
1M ago
EPRX
Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook
PremiumRatings
Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook
1M ago
EPRX
Buy Rating Reaffirmed on EPRX as EP-104GI Catalyst Nears and $16 Price Target Remains Unchanged
PremiumRatings
Buy Rating Reaffirmed on EPRX as EP-104GI Catalyst Nears and $16 Price Target Remains Unchanged
2M ago
EPRX
Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone
PremiumCompany Announcements
Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone
2M ago
6K
EPRX
Eupraxia chief scientific and operating officer Amanda Malone steps down
PremiumThe Fly
Eupraxia chief scientific and operating officer Amanda Malone steps down
2M ago
EPRX
Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances
2M ago
6K
EPRX
Oppenheimer starts Eupraxia at Outperform, sees upside from EoE
Premium
The Fly
Oppenheimer starts Eupraxia at Outperform, sees upside from EoE
2M ago
EPRX
Eupraxia Pharmaceuticals initiated with an Outperform at Oppenheimer
Premium
The Fly
Eupraxia Pharmaceuticals initiated with an Outperform at Oppenheimer
2M ago
EPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >